Home

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Antibodies

Chemical Structure Cat. No. Product Name CAS No.
Nimotuzumab Chemical Structure
BCP25910 Nimotuzumab 828933-51-3;780758-10-3
Nimotuzumab is a humanized monoclonal antibody and binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor).
Adecatumumab Chemical Structure
BCP29455 Adecatumumab 503605-66-1
Adecatumumab is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells.
Ipilimumab Chemical Structure
BCP25419 Ipilimumab 477202-00-9
Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Aducanumab Chemical Structure
BCP24776 Aducanumab 1384260-65-4
Aducanumab targets aggregated forms of β-amyloid (Aβ) in the hopes of reducing its buildup.
Avelumab Chemical Structure
BCP25212 Avelumab 1537032-82-8
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
Durvalumab Chemical Structure
BCP25841 Durvalumab 1428935-60-7
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules.
Pembrolizumab Chemical Structure
BCP24244 Pembrolizumab 1374853-91-4
Pembrolizumab (formerly MK-3475 and lambrolizumab) is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor of lymphocytes.
Ramucirumab Chemical Structure
BCP29228 Ramucirumab 947687-13-0
Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors.It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2).
Eculizumab Chemical Structure
BCP26255 Eculizumab 219685-50-4
Eculizumab is a humanized monoclonal antibody functioning as a terminal complement inhibitor.
Eylea Chemical Structure
BCP29058 Eylea 845771-78-0
Aflibercept is an inhibitor of vascular endothelial growth factor (VEGF).
123下一页末页共 34 条记录 1 / 4 页